This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnston, S. R. D. Articles by Dowsett, M. Search for Related Content PubMed PubMed Citation Articles by Johnston, S. R. D. Articles by Dowsett, M.

Clinical and Endocrine Effects of the Oral Aromatase Inhibitor Vorozole in Postmenopausal Patients with Advanced Breast Cancer

Breast Unit [S. R. D. J., I. E. S., H. R.] and Academic Department of Biochemistry [S. R. D. J., D. D., S. J., M. D.], Royal Marsden Hospital, Fulham Road, London, SW3 6JJ England

Vorozole is an orally active, nonsteroidal aromatase inhibitor. Twenty-four postmenopausal patients with advanced breast cancer who had relapsed after treatment with tamoxifen received three separate daily doses of vorozole (1, 2.5, and 5 mg) each for 1 month in a randomized, double-blind, phase II study. There was significant suppression (P < 0.001) of serum estradiol at all three doses (median reduction, 91, 90, and 89%, respectively). There was a significant trend (P = 0.02) for estradiol to be suppressed below the detection limit of the assay (3 pmol/liter) more frequently with an increasing dose of vorozole; 13, 31, and 40%, respectively. Estrone and estrone-sulfate levels were likewise reduced at each dose by 52–55% and 64–69%, respectively. There was no significant effect at any dose on aldosterone, testosterone, androstenedione, 17-hydroxyprogesterone, or thyroid-stimulating hormone levels. A small reduction in cortisol was seen at the 5 mg dose, although the relevance is unclear given that 17-hydroxyprogesterone levels did not rise. Eight patients (33%) achieved an objective response (2 complete remission, 6 partial remission) with a median response duration of 13 months. Four patients (17%) achieved disease stabilization for more than 6 months. Patients who had responded previously to tamoxifen were more likely to respond to vorozole. There were no significant clinical side effects and the drug was well tolerated. These data suggest that vorozole is a potent and selective oral aromatase inhibitor for use in postmenopausal breast cancer.

¹ To whom requests for reprints should be addressed.

Received 8/ 1/94. Accepted 9/19/94.

This article has been cited by other articles:

				D. J. Handelsman The Rationale for Banning Human Chorionic Gonadotropin and Estrogen Blockers in Sport J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1646 - 1653. [Abstract] [Full Text] [PDF]

				C. L. Harper-Wynne, N. P.M. Sacks, K. Shenton, F. A. MacNeill, P. Sauven, I. J. Laidlaw, Z. Rayter, S. Miall, A. Howes, J. Salter, et al. Comparison of the Systemic and Intratumoral Effects of Tamoxifen and the Aromatase Inhibitor Vorozole in Postmenopausal Patients With Primary Breast Cancer J. Clin. Oncol., February 15, 2002; 20(4): 1026 - 1035. [Abstract] [Full Text] [PDF]

				A. Buzdar and A. Howell Advances in Aromatase Inhibition: Clinical Efficacy and Tolerability in the Treatment of Breast Cancer Clin. Cancer Res., September 1, 2001; 7(9): 2620 - 2635. [Full Text] [PDF]

				K. P. Nephew, E. Osborne, R. A. Lubet, C. J. Grubbs, and S. A. Khan Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat Experimental Biology and Medicine, March 1, 2000; 223(3): 288 - 294. [Abstract] [Full Text]

				P. E. Goss, E. P. Winer, I. F. Tannock, and L. H. Schwartz on behalf of the North American Vorozole Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients J. Clin. Oncol., January 1, 1999; 17(1): 52 - 52. [Abstract] [Full Text] [PDF]

				T. Utsumi, N. Yoshimura, S. Takeuchi, J. Ando, M. Maruta, K. Maeda, and N. Harada Steroid Sulfatase Expression Is an Independent Predictor of Recurrence in Human Breast Cancer Cancer Res., January 1, 1999; 59(2): 377 - 381. [Abstract] [Full Text] [PDF]